CORT — Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on NASDAQ. It is led by Joseph K. Belanoff M.D., based in 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065, with about 730 employees. Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Latest reported CORT revenue for 2025-09-30 was $207.6M. Net income was $75.4M. Revenue was up 6.8% from 2025-06-30 to 2025-09-30. CORT currently screens at market cap $7.46B and trailing P/E 198.5.

Use this CORT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CORT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CORT SEC filings page. Lician reads the product cache first so this HTML stays unique to Corcept Therapeutics Incorporated even when a live quote feed is slow.